Trevena, Inc. (TRVN) Research
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
Market snapshot
- Symbol
- TRVN
- Price
- $0.01
- Day change
- +1010.00%
- Market cap
- $9.6K
- P/E ratio
- -0.00x
- 52-week range
- 0.001-1.93
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Peer companies
Recent insider activity
- Sutton Katrine — trade (0 shares) on 2024-11-26
- Sutton Katrine — trade (76 shares) on 2024-11-26
- Demitrack Mark — F-InKind (20 shares) on 2024-10-08
- Demitrack Mark — F-InKind (45 shares) on 2024-10-08
- Demitrack Mark — F-InKind (144 shares) on 2024-10-08
Open Trevena, Inc. (TRVN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.